24th November, 2022

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Update on USFDA inspection at Cipla's manufacturing facility in Goa

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to intimation dated 26th August, 2022 for United States Food and Drug Administration (USFDA) inspection of our Goa manufacturing facility, we wish to inform you that the Company has received a communication from the USFDA that the classification of Company's said facility continues to be as Official Action Indicated ("OAI"). USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved. The Company has an ongoing derisking plan in place for new product approvals. The Company will work closely with the USFDA and is committed to address these within the stipulated time.

Kindly take the above information on record.

Thanking you,
Yours faithfully,
For Cipla Limited

RAJENDRA KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA
Date: 2022.11.24 10:38:48 +05'30'

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode